HomepageGRFS • NASDAQ
add
Grifols
Vorige slotkoers
$ 7,21
Dag-range
$ 7,14 - $ 7,31
Jaar-range
$ 5,79 - $ 9,96
Beurswaarde
5,98 mld. USD
Gem. volume
981,61K
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,98 mld. | 11,66% |
Bedrijfskosten | 353,12 mln. | 20,32% |
Netto inkomsten | 68,97 mln. | 76,86% |
Netto winstmarge | 3,49 | 58,64% |
Winst per aandeel | — | — |
EBITDA | 495,68 mln. | -11,49% |
Effectief belastingtarief | 60,20% | — |
Balans
Totale activa
Totale passiva
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 1,00 mld. | 55,40% |
Totale activa | 21,41 mld. | 1,97% |
Totale passiva | 12,80 mld. | -5,05% |
Totaal aandelenvermogen | 8,61 mld. | — |
Uitstaande aandelen | 680,41 mln. | — |
Koers-boekwaardeverhouding | 0,83 | — |
Rendement op activa | 5,08% | — |
Rendement op kapitaal | 5,79% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 68,97 mln. | 76,86% |
Operationele kasstroom | 514,62 mln. | 208,54% |
Kasstroom uit beleggingen | -178,31 mln. | -28,31% |
Kasstroom uit financiering | -27,16 mln. | -185,08% |
Nettomutatie in liquide middelen | 334,84 mln. | 658,87% |
Vrije kasstroom | 162,44 mln. | 123,56% |
Over
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Opgericht
18 nov 1940
Website
Werknemers
23.833